Neurology
Page 2 • 5 itemsGain critical insights into global neurology drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
Methylphenidate Shortage Update: Concerta and Ritalin LA Supply Restored, Rubifen LA Expected by June 2026
Australia's methylphenidate shortage shows improvement as Concerta and Ritalin LA supplies normalize, while Rubifen LA shortages persist until mid-2026.
P&G Health Launches First APAC Pharmacist Guidelines for Peripheral Neuropathy Management
P&G Health and APAC experts release region's first community pharmacist guidelines for peripheral neuropathy, affecting 1 in 2 diabetics and 1 in 10 adults.
Phantom Neuro Receives Approval for First Human Trial of Phantom X Neural Interface System
Phantom Neuro gets approval for first-in-human trial of Phantom X neural interface system in Australia, marking major milestone for prosthetic control technology.
XellSmart Advances XS411 Parkinson's Cell Therapy to Phase II Trial After Positive Phase I Results
XellSmart launches multicenter Phase II trial for XS411, an iPSC-derived dopaminergic cell therapy for Parkinson's disease following encouraging Phase I data.
Telix Pharmaceuticals Doses First Patient in Phase 3 Trial of TLX101-Tx for Recurrent Glioblastoma
Telix begins Phase 3 IPAX-BrIGHT trial of TLX101-Tx, marking the first radiopharmaceutical therapy to reach Phase 3 for recurrent glioblastoma treatment.